Peripartum Cardiomyopathy with the Cardiac Function Restored by Cabergoline

Intern Med. 2023 Jul 15;62(14):2085-2088. doi: 10.2169/internalmedicine.0988-22. Epub 2022 Nov 23.

Abstract

Peripartum cardiomyopathy (PPCM) is a left ventricular systolic dysfunction associated with heart failure (HF) in late-term pregnancy or peripartum. A 29-year-old pregnant woman with no history of cardiac disease noted lower extremity edema around 34 weeks' gestation with significant weight gain. She delivered twins via caesarean section, and the edema regressed postpartum. On postpartum day 4, however, she experienced difficulty breathing at night and was diagnosed with HF owing to PPCM. HF treatment along with cabergoline was initiated. With low prolactin blood levels, her symptoms and cardiac function improved over time. This case demonstrated the usefulness of anti-prolactin therapy with cabergoline in PPCM.

Keywords: cabergoline; cardiac function; heart failure; peripartum cardiomyopathy; pregnancy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Cabergoline / therapeutic use
  • Cardiomyopathies* / diagnosis
  • Cesarean Section
  • Female
  • Heart Failure* / drug therapy
  • Heart Failure* / etiology
  • Humans
  • Peripartum Period
  • Pregnancy
  • Pregnancy Complications, Cardiovascular* / diagnosis
  • Pregnancy Complications, Cardiovascular* / drug therapy
  • Puerperal Disorders* / diagnosis
  • Puerperal Disorders* / drug therapy

Substances

  • Cabergoline